Skip to content
Homepage
Author:
VERAXA Biotech GmbH
Posted Date:
July 10, 2026
VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister
VERAXA Biotech GmbH
July 10, 2026
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
VERAXA Biotech GmbH
July 6, 2026
VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program
VERAXA Biotech GmbH
July 2, 2026
VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development
VERAXA Biotech GmbH
June 24, 2026
VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026
VERAXA Biotech GmbH
June 18, 2026
VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026
VERAXA Biotech GmbH
June 10, 2026
VERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase Agreement
VERAXA Biotech GmbH
May 28, 2026
VERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.
VERAXA Biotech GmbH
March 2, 2026
